Trulieve Set to List on NYSE

Ganjapreneur
Mon, Jun 8
Key Points
  • Trulieve Cannabis Corp. plans to begin trading on the New York Stock Exchange (NYSE) under the symbol “TRLV” starting June 10, 2026.
  • The move follows the federal rescheduling of state-legal medical cannabis from Schedule I to Schedule III, opening new legal opportunities for state-licensed medical cannabis companies.
  • Trulieve, operating in Florida, Georgia, Pennsylvania, and West Virginia, is uplisting from the Canadian Securities Exchange (CSE) and OTCQX to the NYSE to expand its shareholder base and increase liquidity.
  • The company has invested heavily in cannabis legalization efforts in Florida, donating over $140 million in 2024 and $19.6 million in 2026 campaigns, both of which were unsuccessful.

Florida-based multi-state medical cannabis operator Trulieve Cannabis Corp. announced last week that the company expects to begin trading on the New York Stock Exchange (NYSE) under the symbol “TRLV” starting June 10, 2026.

The announcement follows the rescheduling of state-legal medical cannabis from Schedule I to Schedule III under federal law, creating new legal pathways and opportunities for state-licensed medical cannabis companies.

“As the first U.S. cannabis company to list on a major U.S. exchange, we are excited for the opportunity to expand our shareholder base, increase liquidity, and raise awareness for the benefits of medical marijuana. Common sense action by President Trump to reclassify medical marijuana to Schedule III paved the way for this historic milestone. Uplisting to the NYSE is a major advancement for Trulieve and the industry.” — Kim Rivers, Trulieve Founder and CEO, in a statement

Trulieve operates state-licensed cannabis businesses in Florida, Georgia, Pennsylvania, and West Virginia.

The multi-state operator is uplisting to the NYSE after being previously listed on the Canadian Securities Exchange (CSE) under the symbol “TRUL” and OTCQX under the symbol “TCNNF.”

Trulieve famously donated heavily to Florida’s failed 2024 cannabis legalization, bringing over $140 million to the effort. The company also contributed $19.6 million to the campaign’s unsuccessful bid for 2026.